Search PubMed⌕ Search

Biomedical subjects

P Watkins

Publications and source records attributed to P Watkins.

At least 73 records · Page 4Linked to original sources

Purification and characterization of altered cystic fibrosis liver alpha-L-fucosidase.

alpha-L-Fucosidase (E.C.3.2.4.51) from two cystic fibrosis livers has been purified and characterized. Purification was accomplished by an affinity chromatographic procedure previously used for normal liver alpha-L-fucosidase. Characterization of the two cystic fibrosis alpha-L-fucosidases indicated that they were very similar to normal liver alpha-L-fucosidase with regard to pH optima profiles, Michaelis constants (Km's), subunit structure and antigenicity. However, gas liquid chromatographic analysis revealed altered carbohydrate compositions for both the cystic fibrosis alpha-L-fucosidases. The three major sugars found in normal purified liver alpha-L-fucosidase (mannose, N-acetylglucosamine and sialic acid) were reduced in the cystic fibrosis alpha-L-fucosidases, on average, to 51%, 44% and 32%, respectively, of their normal amounts.

Carbohydrates↗

Insulin control of glucose metabolism in man: a new kinetic analysis.

Analyses of the control of glucose metabolism by insulin have been hampered by changes in bloog glucose concentration induced by insulin administration with resultant activation of hypoglycemic counterregulatory mechanisms. To eliminate such mechanisms, we have employed the glucose clamp technique which allows maintenance of fasting blood glucose concentration during and after the administration of insulin. Analyses of six studies performed in young healthy men in the postabsorptive state utilizing the concurrent administration of [14C]glucose and 1 mU/kg per min (40 mU/m2 per min) porcine insulin led to the development of kinetic models for insulin and for glucose. These models account quantitatively for the control of insulin on glucose utilization and on endogenous glucose production during nonsteady states. The glucose model, a parallel three-compartment model, has a central compartment (mass = 68 +/- 7 mg/kg; space of distribution = blood water volume) in rapid equilibrium with a smaller compartment (50 +/- 17 mg/kg) and in slow equilibrium with a larger compartment (96 +/-21 mg/kg). The total plasma equivalent space for the glucose system averaged 15.8 liters or 20.3% body weight. Two modes of glucose loss are introduced in the model. One is a zero-order loss (insulin and glucose independent) from blood to the central nervous system; its magnitude was estimated from published data. The other is an insulin-dependent loss, occurring from the rapidly equilibrating compartment and, in the basal period, is smaller than the insulin-independent loss. Endogenous glucose production averaged 1.74 mg/kg per min in the basal state and enters the central compartment directly. During the glucose clamp experiments plasma insulin levels reached a plateau of 95 +/-8 microU/ml. Over the entire range of insulin levels studied, glucose losses were best correlated with levels of insulin in a slowly equilibrating insulin compartment of a three-compartment insulin model. A proportional control by this compartment on glucose utilization was adequate to satisfy the observed data. Insulin also rapidly decreased the endogenous glucose production to 33% of its basal level (0.58 mg/kg per min), this suppression being maintained for at least 40 min after exogenous insulin infusion was terminated and after plasma insulin concentrations had returned to basal levels. The change in glucose utilization per unit change in insulin in the slowly equilibrating insulin compartment is proposed as a new measure for insulin sensitivity. This defines insulin effects more precisely than previously used measures, such as plasma glucose/plasma insulin concentration ratios. Glucose clamp studies and the modeling of the coupled kinetics of glucose and insulin offers a new and potentially valuable tool to the study of altered states of carbohydrate metabolism.

Adolescent↗

Evidence against Ha-ras-1 involvement in sporadic and familial melanoma.

It was recently reported that different rare alleles at the Ha-ras-1 locus occurred at a significantly higher combined frequency in cancer patients than in an unaffected population. In particular, melanoma patients were reported to have a significantly higher frequency of such alleles. We have examined the frequency of rare Ha-ras-1 alleles in a large number of cases of sporadic melanoma. Our results indicate that the distribution of rare alleles in this population does not differ from that found in normal populations. Also, to test the hypothesis that a hereditary predisposition to melanoma could be inherited via an allele at the Ha-ras-1 locus, we examined the transmission of the segment of the short arm of chromosome 11 (11p) carrying the Ha-ras-1 locus in a number of families previously shown to exhibit a hereditary predisposition to melanoma and its precursor lesion, the dysplastic nevus syndrome (DNS). Our genetic linkage results thus obtained strongly exclude the association of a predisposition to melanoma or the precursor lesion with the inheritance of the Ha-ras-1 locus or the segment of chromosome 11 on which it is located. These results imply that hereditary predisposition to melanoma is associated with genes other than the Ha-ras-1 locus, contradicting the original suggestion of Krontiris et al., made on the basis of either an inadequate sample size or other misleading experimental factors.

Alleles↗

Treatment of cytomegalovirus pneumonia.

In a multicenter uncontrolled trial of ganciclovir therapy for well-documented cytomegalovirus (CMV) pneumonia in 21 patients following bone marrow transplantation, eight (38%) of 21 survived for more than 90 days. Two additional patients responded to ganciclovir therapy; one survived for 60 days before relapsing with fatal CMV pneumonia, and the other survived 79 days before dying with disseminated aspergillosis. No CMV disease was found in this latter patient at autopsy. The improved survival of patients in this trial may be due to a small number of patients (23%) who developed significant neutropenia during ganciclovir therapy, to the concurrent use of CMV immune globulin in three of the survivors, or to other variables affecting a positive outcome. Data on the use of CMV DNA-DNA hybridization assays to detect CMV DNA directly in patients' blood suggest that this method may be useful in following the clearance of CMV viremia in patients receiving ganciclovir. The results of treatment of CMV pneumonia in bone marrow transplant recipients are compared with those of previous studies, of CMV pneumonia in renal transplant recipients, and of CMV pneumonia in patients with AIDS. Suggestions for further, more definitive, studies of CMV pneumonia are presented.

Acyclovir↗

Identifying and treating plantar warts.

This article aims to help health practitioners to identify plantar warts, and to provide information on available treatments. The efficacy of various treatments is inconclusive. Topical treatments are recommended instead of other often costly and sometimes unsuccessful treatments such as cryotherapy. Improved education and self-management are encouraged to minimise spread of the virus and to ease discomfort.

Antiviral Agents↗

NICE.

Explore the source record for details and available documents.

Humans↗